Lyme Disease PCR, Blood
Document Sample


Lab Dept: Microbiolgy/Virology
Test Name: LYME DISEASE PCR, BLOOD
General Information
Lab Order Codes: LYPCB
Synonyms: Borrelia burgdorferi PCR; Lyme Disease PCR; Lyme Disease by
Polymerase Chain Reaction
CPT Codes: 87476 – Borrelia burgdorferi, amplified probe technique
Test Includes: A positive or negative result indicating the presence or absence of Borrelia
burgdorferi DNA in the specimen submitted.
Logistics
Test Indications: Confirmation of active Lyme Disease. Monitoring Lyme Disease treatment.
Diagnosing and monitoring Lyme arthritis.
PCR testing should be limited to patients with at least an equivocal or
positive serologic test for antibody to Borrelia burgdorferi.
Lab Testing Sections: Microbiology/Virology – Sendouts
Referred to: Mayo Medical Laboratories (MML Test# 87973)
Phone Numbers:
Minneapolis: 612-813-6280
Saint Paul: 651-220-6550
Test Availability: Daily, 24 hours
Turnaround Time: 1 – 4 days
Special Instructions: N/A
Specimen
Specimen Type: Whole blood
Container: Lavender (EDTA) top
Draw Volume: 1.0 mL (Minimum: 0.5 mL) whole blood
Processed Volume: Same as Draw Volume
Collection: Rputine venipuncture
Special Processing: Lab Staff: Do Not centrifuge. Submit specimen in original collection
container. Maintain sterility. Store at ship at refrigerated temperatures.
Patient Preparation: None
Sample Rejection: Mislabeled or unlabeled specimens
Interpretive
Reference Range: Negative (reported as positive or negative)
Critical Values: N/A
Limitations: A negative result does not rule out Lyme disease, since inhibitory
substances may be present in the specimen and the assay has limited
diagnostic sensitivity when testing certain types of specimens. If clinical
features of illness are highly indicative of Lyme neuroborreliosis, serologic
testing on CSF is warranted.
Patients with active infection due to Borrelia afzelii, or Borrelia garinii may
have positive results from this PCR test, which can distinguish Borrelia
burgdorferi infection from those of Borrelia afzelii and Borrelia garinii.
However, the later 2 infections are indistinguishable from one another by
this PCR assay. Specimens with detectable DNA from either of these two
sprirochetes in this assay will be reported as “positive” for Borrelia
afzelii/Borrelia garini”.
PCR test results should be used as an aid in diagnosis and not considered
diagnostic by themselves. These results should be correlated with serologic
and epidemiologic data and clinical presentation of the patient.
Coinfection with Erhlichia chaffeensis/Anaplasma phagocytophilum and/or
Babesia microti have been reported in the United States.
Methodology: Polymerase Chain Reaction (PCR)/DNA Probe Hybridization
(PCR is utilized pursuant to a license agreement with Roche Molecular
Systems, Inc.)
References: Mayo Medical Laboratories Web Page November 2009
Related docs
Get documents about "